Results 151 to 160 of about 13,157 (218)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers. [PDF]

Int J Chron Obstruct Pulmon Dis, 2020
Singer D, Bengtson LGS, Elliott C, Buikema AR, Franchino-Elder J.   +4 more
europepmc   +1 more source

Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan

International Journal of COPD, 2018
Keiji Oishi,1 Tsunahiko Hirano,2 Kazuki Hamada,2 Sho Uehara,2 Ryo Suetake,2 Yoshikazu Yamaji,2 Kosuke Ito,2 Maki Asami-Noyama,2 Nobutaka Edakuni,2 Kazuto Matsunaga2 1Department of Medicine and Clinical Science, Graduate School of Medicine, Yamaguchi ...
Oishi K, Hirano T, Hamada K, Uehara S, Suetake R, Yamaji Y, Ito K, Asami-Noyama M, Edakuni N, Matsunaga K   +9 more
doaj  

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease. [PDF]

Drugs Real World Outcomes, 2020
Roberts MH, Mapel DW, Petersen H.
europepmc   +1 more source

Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective. [PDF]

Drugs
Cazzola M, Page CP, Calzetta L, Martinez FJ, Rogliani P, Matera MG.   +5 more
europepmc   +1 more source

Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.

Respiration, 2021
Lee HW, Kim HJ, Jang EJ, Lee CH.
europepmc   +1 more source

The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro. [PDF]

Respir Res
Matera MG, Rinaldi B, Calabrese C, Belardo C, Calzetta L, Cazzola M, Page C.   +6 more
europepmc   +1 more source

Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial). [PDF]

Circ Rep
Hayashi H, Ito S, Fukuda H, Sata M, Abe Y, Fujimoto K, Fukuda D, Hanajima Y, Horii M, Ikehara N, Inoko M, Izumi C, Izumiya Y, Nakayama T, Sozu T, Toyoda S, Watanabe M, Yokoi M, Kitakaze M.   +18 more
europepmc   +1 more source

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD

, 2017
Raju Bishwakarma,1 Wei Zhang,1 Yong-Fang Kuo,2,3 Gulshan Sharma1,3 1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 2Office of Biostatistics, 3Sealy Center of Aging, University of Texas Medical Branch, Galveston,
Zhang W, Kuo YF, Sharma G, Bishwakarma R
core  

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate. [PDF]

Chronic Obstr Pulm Dis, 2019
Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD.   +5 more
europepmc   +1 more source

Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma [PDF]

, 2017
Diana M. Sobieraj, William L. Baker, Erin R. Weeda, Elaine Nguyen, Craig I. Coleman, C. Michael White, Stephen C. Lazarus, Kathryn V. Blake, Jason E. Lang   +8 more
openaire   +1 more source